npj Parkinsons Disease

Article	Citations
Meta-analysis of the Parkinson’s disease gut microbiome suggests alterations linked to intestinal inflammation	362
Incidence of Parkinson disease in North America	95
Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease	79
Gastrointestinal involvement in Parkinson’s disease: pathophysiology, diagnosis, and management	74
Toward therapeutic electrophysiology: beta-band suppression as a biomarker in chronic local field potential recordings	66
Dynamic control of the dopamine transporter in neurotransmission and homeostasis	65
Genetic and environmental factors in Alzheimer’s and Parkinson’s diseases and promising therapeutic intervention via fecal microbiota transplantation	64
Neuroimaging evidence of glymphatic system dysfunction in possible REM sleep behavior disorder and Parkinson’s disease	63
Multi-modality machine learning predicting Parkinson’s disease	63
Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson’s disease and other synucleinopathies	61
Subthalamic and pallidal deep brain stimulation for Parkinson’s disease—meta-analysis of outcomes	60
A postmortem study suggests a revision of the dual-hit hypothesis of Parkinson’s disease	60
Diagnostic value of skin RT-QuIC in Parkinson’s disease: a two-laboratory study	59
The impact of COVID-19 and social distancing on people with Parkinson’s disease: a survey study	59
How COVID-19 will boost remote exercise-based treatment in Parkinson’s disease: a narrative review	57
Neurofilament light chain and α-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes	57
Is LRRK2 the missing link between inflammatory bowel disease and Parkinson’s disease?	54
Probiotics synergized with conventional regimen in managing Parkinson’s disease	54
Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson’s disease	53
A systematic review on exercise and training-based interventions for freezing of gait in Parkinson’s disease	52
Mechanisms of peripheral levodopa resistance in Parkinson’s disease	51
Gait speed in clinical and daily living assessments in Parkinson’s disease patients: performance versus capacity	49
Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology	48
Timing variability and midfrontal ~4 Hz rhythms correlate with cognition in Parkinson’s disease	47
Plasma-borne indicators of inflammasome activity in Parkinson’s disease patients	46

Diffusion along perivascular spaces as marker for impairment of glymphatic system in Parkinson’s disease	45
Eight-hours conventional versus adaptive deep brain stimulation of the subthalamic nucleus in Parkinson’s disease	42
Oleh Hornykiewicz, a giant in the understanding and treatment of Parkinson disease	42
The role of brain perivascular space burden in early-stage Parkinson’s disease	41
A nationwide study of the incidence, prevalence and mortality of Parkinson’s disease in the Norwegian population	41
Stress and mindfulness in Parkinson’s disease – a survey in 5000 patients	41
Clinical utility of DaTscan in patients with suspected Parkinsonian syndrome: a systematic review and meta-analysis	41
Dynamic physiological α-synuclein S129 phosphorylation is driven by neuronal activity	40
Diurnal modulation of subthalamic beta oscillatory power in Parkinson’s disease patients during deep brain stimulation	38
A systematic review and meta-analysis of inflammatory biomarkers in Parkinson’s disease	37
Astrocytic atrophy as a pathological feature of Parkinson’s disease with LRRK2 mutation	37
Lewy body disease or diseases with Lewy bodies?	36
Early constipation predicts faster dementia onset in Parkinson’s disease	36
Perspective on the current state of the LRRK2 field	36
Detection of SARS-CoV-2 viral proteins and genomic sequences in human brainstem nuclei	36
Mining imaging and clinical data with machine learning approaches for the diagnosis and early detection of Parkinson’s disease	36
Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in Parkinson’s disease	35
Fine mapping of the HLA locus in Parkinson’s disease in Europeans	35
Cofilin 1 promotes the pathogenicity and transmission of pathological α-synuclein in mouse models of Parkinson’s disease	35
A transcriptome-wide association study identifies susceptibility genes for Parkinson’s disease	35
Subthalamic beta bursts correlate with dopamine-dependent motor symptoms in 106 Parkinson’s patients	34
Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study	34
Parkinson’s disease multimodal imaging: F-DOPA PET, neuromelanin-sensitive and quantitative iron-sensitive MRI	33
Nitrosative stress in Parkinson’s disease	33
Long-term effect of apomorphine infusion in advanced Parkinson’s disease: a real-life study	33
Reference SVA insertion polymorphisms are associated with Parkinson’s Disease progression and differential gene expression	33
Rheumatoid arthritis decreases risk for Parkinson’s disease: a Mendelian randomization study	32
Acquired dysregulation of dopamine homeostasis reproduces features of Parkinson’s disease	32
Specific immune status in Parkinson’s disease at different ages of onset	32
Plasma branched-chain and aromatic amino acids correlate with the gut microbiota and severity of Parkinson’s disease	31
A systematic review and meta-analysis on effects of aerobic exercise in people with Parkinson’s disease	31
Effects of the agility boot camp with cognitive challenge (ABC-C) exercise program for Parkinson’s disease	31
Reduced astrocytic reactivity in human brains and midbrain organoids with PRKN mutations	31
Reduced synaptic activity and dysregulated extracellular matrix pathways in midbrain neurons from Parkinson’s disease patients	30
Gender gap in deep brain stimulation for Parkinson’s disease	30
Sex-based differences in the activation of peripheral blood monocytes in early Parkinson disease	29
A real-world study of wearable sensors in Parkinson’s disease	29
α-Synuclein aggregation in the olfactory bulb induces olfactory deficits by perturbing granule cells and granular–mitral synaptic transmission	29
Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease	28
Pathways to Parkinson’s disease: a spotlight on 14-3-3 proteins	28
Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology	28
Prognostic biomarkers of Parkinson’s disease in the Spanish EPIC cohort: a multiplatform metabolomics approach	27
Oral and gut dysbiosis leads to functional alterations in Parkinson’s disease	27
Parkinson’s disease clinical milestones and mortality	27
Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease	26
Mitophagy and reactive oxygen species interplay in Parkinson’s disease	26
A review on pathology, mechanism, and therapy for cerebellum and tremor in Parkinson’s disease	26
Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages	25
Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic Parkinson’s disease enrolled in PPMI	25
“Hot cross bun” is a potential imaging marker for the severity of cerebellar ataxia in MSA-C	25

Astrogliosis and sexually dimorphic neurodegeneration and microgliosis in the olfactory bulb in Parkinson’s disease	25
A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease	25
Alpha-synuclein oligomers and small nerve fiber pathology in skin are potential biomarkers of Parkinson’s disease	25
Parkinson’s disease-associated, sex-specific changes in DNA methylation at PARK7 (DJ-1), SLC17A6 (VGLUT2), PTPRN2 (IA-2β), and NR4A2 (NURR1) in cortical neurons	25
Plasma GFAP in Parkinson’s disease with cognitive impairment and its potential to predict conversion to dementia	24
Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons	24
Irritable bowel syndrome and Parkinson’s disease risk: register-based studies	23
Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures	23
Multimodal phenotypic axes of Parkinson’s disease	23
Thalamic morphology predicts the onset of freezing of gait in Parkinson’s disease	23
RETRACTED ARTICLE: Non-invasive vagus nerve stimulation improves clinical and molecular biomarkers of Parkinson’s disease in patients with freezing of gait	23
Distinct patterns of speech disorder in early-onset and late-onset de-novo Parkinson’s disease	23
Glycation modulates glutamatergic signaling and exacerbates Parkinson’s disease-like phenotypes	23
Parkinson’s disease patients’ short chain fatty acids production capacity after in vitro fecal fiber fermentation	22
The potential convergence of NLRP3 inflammasome, potassium, and dopamine mechanisms in Parkinson’s disease	22
Potent inhibitors of toxic alpha-synuclein identified via cellular time-resolved FRET biosensors	22
Computer vision quantification of whole-body Parkinsonian bradykinesia using a large multi-site population	22
LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease	22
Insights into the multifaceted role of circular RNAs: implications for Parkinson’s disease pathogenesis and diagnosis	22
A blinded, controlled trial of objective measurement in Parkinson’s disease	22
Synucleinopathy-associated pathogenesis in Parkinson’s disease and the potential for brain-derived neurotrophic factor	22
Revisiting the specificity and ability of phospho-S129 antibodies to capture alpha-synuclein biochemical and pathological diversity	21
Angiotensin type-1 receptor and ACE2 autoantibodies in Parkinson´s disease	21
DAT and TH expression marks human Parkinson’s disease in peripheral immune cells	21
Identification and prediction of Parkinson’s disease subtypes and progression using machine learning in two cohorts	21
A proteogenomic view of Parkinson’s disease causality and heterogeneity	21
α-Synuclein-induced dysregulation of neuronal activity contributes to murine dopamine neuron vulnerability	21
A nationwide cohort study on diabetes severity and risk of Parkinson disease	20
Cerebro-cerebellar motor networks in clinical subtypes of Parkinson’s disease	20
Balance response to levodopa predicts balance improvement after bilateral subthalamic nucleus deep brain stimulation in Parkinson’s disease	20
Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease	19
Protection from α-Synuclein induced dopaminergic neurodegeneration by overexpression of the mitochondrial import receptor TOM20	19
Behavioural and neuroplastic effects of a double-blind randomised controlled balance exercise trial in people with Parkinson’s disease	19
High neutrophil-to-lymphocyte ratio predicts short survival in multiple system atrophy	19
Irisin exhibits neuroprotection by preventing mitochondrial damage in Parkinson’s disease	19
Melatonin ameliorates Parkinson’s disease via regulating microglia polarization in a RORα‐dependent pathway	19
Linking environmental risk factors with epigenetic mechanisms in Parkinson’s disease	19
Altered neural cell junctions and ion-channels leading to disrupted neuron communication in Parkinson’s disease	19
Combining skin and olfactory α-synuclein seed amplification assays (SAA)—towards biomarker-driven phenotyping in synucleinopathies	19
Exploring human-genome gut-microbiome interaction in Parkinson’s disease	18
A systematic review of associations between common SNCA variants and clinical heterogeneity in Parkinson’s disease	18
Exosome markers of LRRK2 kinase inhibition	18
Expediting telehealth use in clinical research studies: recommendations for overcoming barriers in North America	18
Improving estimation of Parkinson’s disease risk—the enhanced PREDICT-PD algorithm	18
Probable REM sleep behavior disorder is associated with longitudinal cortical thinning in Parkinson’s disease	18
C/EBPβ/AEP is age-dependently activated in Parkinson’s disease and mediates α-synuclein in the gut and brain	18
Association between inflammatory bowel disease and Parkinson’s disease: A Mendelian randomization study	18
Quantitative detection of α-Synuclein and Tau oligomers and other aggregates by digital single particle counting	18
Imaging mass cytometry reveals generalised deficiency in OXPHOS complexes in Parkinson’s disease	18
The CloudUPDRS smartphone software in Parkinson’s study: cross-validation against blinded human raters	18
Parkinson’s disease patients benefit from bicycling - a systematic review and meta-analysis	18
Validation of the PD home diary for assessment of motor fluctuations in advanced Parkinson’s disease	18
Gut bacterial tyrosine decarboxylase associates with clinical variables in a longitudinal cohort study of Parkinsons disease	18
Patients with isolated REM-sleep behavior disorder have elevated levels of alpha-synuclein aggregates in stool	17
Genome-wide association study using whole-genome sequencing identifies risk loci for Parkinson’s disease in Chinese population	17
Weeding through the haze: a survey on cannabis use among people living with Parkinson’s disease in the US	17
Biallelic expansion in RFC1 as a rare cause of Parkinson’s disease	17
DOPAL initiates αSynuclein-dependent impaired proteostasis and degeneration of neuronal projections in Parkinson’s disease	17
Similarities and differences between nigral and enteric dopaminergic neurons unravel distinctive involvement in Parkinson’s disease	17
Arm swing responsiveness to dopaminergic medication in Parkinson’s disease depends on task complexity	17
Axial impairment and falls in Parkinson’s disease: 15 years of subthalamic deep brain stimulation	17
Parkinson’s disease patient-specific neuronal networks carrying the LRRK2 G2019S mutation unveil early functional alterations that predate neurodegeneration	16
A randomized controlled double-blind study of rotigotine on neuropsychiatric symptoms in de novo PD	16
Human moral decision-making through the lens of Parkinson’s disease	16
Mutant LRRK2 in lymphocytes regulates neurodegeneration via IL-6 in an inflammatory model of Parkinson’s disease	16
Specific gut microbiota alterations in essential tremor and its difference from Parkinson’s disease	16
Change in the incidence of Parkinson’s disease in a large UK primary care database	16
Comparative proteomic analysis highlights metabolic dysfunction in α-synucleinopathy	16
White matter changes in Parkinson’s disease	15
Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase	15
Cholinesterase inhibitors for gait, balance, and fall in Parkinson disease: a meta-analysis	15
Glycolysis-enhancing α1-adrenergic antagonists modify cognitive symptoms related to Parkinson’s disease	15
Machine learning-based prediction of cognitive outcomes in de novo Parkinson’s disease	15
Shared genetic etiology between Parkinson’s disease and blood levels of specific lipids	15
Impaired reach-to-grasp kinematics in parkinsonian patients relates to dopamine-dependent, subthalamic beta bursts	15
Identification of motor progression in Parkinson’s disease using wearable sensors and machine learning	15
Similar neuronal imprint and no cross-seeded fibrils in α-synuclein aggregates from MSA and Parkinson’s disease	15
Multiomics implicate gut microbiota in altered lipid and energy metabolism in Parkinson’s disease	15
Comprehensive subtyping of Parkinson’s disease patients with similarity fusion: a case study with BioFIND data	15
Predictors of clinically significant quality of life impairment in Parkinson’s disease	15

Adverse effects of hypertension, supine hypertension, and perivascular space on cognition and motor function in PD	14
Estrogen-related receptor gamma regulates mitochondrial and synaptic genes and modulates vulnerability to synucleinopathy	14
Serum lipid profile among sporadic and familial forms of Parkinson’s disease	14
Peripheral inflammatory immune response differs among sporadic and familial Parkinson’s disease	14
White matter and nigral alterations in multiple system atrophy-parkinsonian type	14
A comparative blind study between skin biopsy and seed amplification assay to disclose pathological α-synuclein in RBD	14
An integrated biometric voice and facial features for early detection of Parkinson’s disease	14
Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach	14
Fecal microbiome alterations in treatment-naive de novo Parkinson’s disease	14
Cdk5 phosphorylation-induced SIRT2 nuclear translocation promotes the death of dopaminergic neurons in Parkinson’s disease	14
Corneal nerve fiber loss relates to cognitive impairment in patients with Parkinson’s disease	13
Alterations in the LRRK2-Rab pathway in urinary extracellular vesicles as Parkinson’s disease and pharmacodynamic biomarkers	13
The effect of levodopa on bilateral coordination and gait asymmetry in Parkinson’s disease using inertial sensor	13
Short-term effect of dopaminergic medication on speech in early-stage Parkinson’s disease	13
High content screening and proteomic analysis identify a kinase inhibitor that rescues pathological phenotypes in a patient-derived model of Parkinson’s disease	13
Cerebrospinal fluid biomarkers in Parkinson’s disease with freezing of gait: an exploratory analysis	13
DBS-evoked cortical responses index optimal contact orientations and motor outcomes in Parkinson’s disease	13
Delayed orthostatic hypotension in Parkinson’s disease	13
Gut microbiota in dementia with Lewy bodies	13
Technology-based therapy-response and prognostic biomarkers in a prospective study of a de novo Parkinson’s disease cohort	13
Harmol promotes α-synuclein degradation and improves motor impairment in Parkinson’s models via regulating autophagy-lysosome pathway	13
Parkinsonism mutations in DNAJC6 cause lipid defects and neurodegeneration that are rescued by Synj1	13
Different pieces of the same puzzle: a multifaceted perspective on the complex biological basis of Parkinson’s disease	13
Distinct profiles of LRRK2 activation and Rab GTPase phosphorylation in clinical samples from different PD cohorts	13
Elevation of gangliosides in four brain regions from Parkinson’s disease patients with a GBA mutation	13